Clinical trial
Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia…
NCT00003757 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003757 |
|---|---|
| Title | Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy |
| Official title | Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA) |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | rituximab |
| Enrollment | 25 |
| Start date | Feb 1, 1998 |
| Primary completion | Jul 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Apr 30, 2003 |
| Last update posted | May 15, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: